scholarly journals Fibroblast growth factor 21 coordinates adiponectin to mediate the beneficial effects of low-protein diet on primordial follicle reserve

EBioMedicine ◽  
2019 ◽  
Vol 41 ◽  
pp. 623-635 ◽  
Author(s):  
Yong Zhuo ◽  
Lun Hua ◽  
Bin Feng ◽  
Xuemei Jiang ◽  
Jing Li ◽  
...  
Nutrients ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 1504
Author(s):  
Susanna C. Larsson ◽  
Dipender Gill

Fibroblast growth factor 21 (FGF21) is a human metabolic hormone whose effects include modification of macronutrient preference and energy homeostasis. In animal models, FGF21 has been shown to have beneficial effects on cardiometabolic outcomes, Alzheimer’s disease risk and lifespan. In this study, the single-nucleotide polymorphism rs838133 in the FGF21 gene region was leveraged to investigate the potential clinical effects of targeting FGF21. The FGF21 G allele was associated with lower intakes of total sugars and alcohol, and higher intakes of protein and fat as well as favourable with lipid levels, blood pressure traits, waist-to-hip ratio, systemic inflammation, cardiovascular outcomes, Alzheimer’s disease risk and lifespan. These findings may be used to anticipate the effects of pharmacologically increasing FGF21 signalling.


2021 ◽  
Vol 12 ◽  
Author(s):  
Mengjie Xiao ◽  
Yufeng Tang ◽  
Shudong Wang ◽  
Jie Wang ◽  
Jie Wang ◽  
...  

Fibroblast growth factor 21 (FGF21), is an emerging metabolic regulator mediates multiple beneficial effects in the treatment of metabolic disorders and related complications. Recent studies showed that FGF21 acts as an important inhibitor in the onset and progression of cardiovascular complications of diabetes mellitus (DM). Furthermore, evidences discussed so far demonstrate that epigenetic modifications exert a crucial role in the initiation and development of DM-related cardiovascular complications. Thus, epigenetic modifications may involve in the function of FGF21 on DM-induced cardiovascular complications. Therefore, this review mainly interprets and delineates the recent advances of role of FGF21 in DM cardiovascular complications. Then, the possible changes of epigenetics related to the role of FGF21 on DM-induced cardiovascular complications are discussed. Thus, this article not only implies deeper understanding of the pathological mechanism of DM-related cardiovascular complications, but also provides the possible novel therapeutic strategy for DM-induced cardiovascular complications by targeting FGF21 and related epigenetic mechanism.


2015 ◽  
Vol 227 (2) ◽  
pp. R13-R30 ◽  
Author(s):  
Pongpan Tanajak ◽  
Siriporn C Chattipakorn ◽  
Nipon Chattipakorn

Fibroblast growth factor 21 (FGF21) is a novel polypeptide ligand that has been shown to be involved in several physiological and pathological processes including regulation of glucose and lipids as well as reduction of arteriosclerotic plaque formation in the great vessels. It has also been shown to exert cardioprotective effects in myocardial infarction, cardiac ischemia-reperfusion injury, cardiac hypertrophy and diabetic cardiomyopathy. Moreover, FGF21 protects the myocardium and great arteries by attenuating remodeling, inflammation, oxidative stress and also promoting the energy supply to the heart through fatty acid β-oxidation. This growing evidence emphasizes the important roles of FGF21 in cardioprotection. This review comprehensively summarizes and discusses the consistent and inconsistent findings regarding the beneficial effects of FGF21 on the heart available from both basic research and clinical reports. The details of the signaling, biological and pharmacological effects of FGF21 with regard to its protection of the heart are also presented and discussed in this review.


Lipids ◽  
2014 ◽  
Vol 49 (11) ◽  
pp. 1081-1089 ◽  
Author(s):  
Joan Villarroya ◽  
Pavel Flachs ◽  
Ibon Redondo-Angulo ◽  
Marta Giralt ◽  
Dasa Medrikova ◽  
...  

2015 ◽  
Vol 2015 ◽  
pp. 1-11 ◽  
Author(s):  
Ravneet K. Boparai ◽  
Oge Arum ◽  
Johanna G. Miquet ◽  
Michal M. Masternak ◽  
Andrzej Bartke ◽  
...  

Fibroblast growth factor 21 (FGF21) modulates a diverse range of biological functions, including glucose and lipid metabolism, adaptive starvation response, and energy homeostasis, but with limited mechanistic insight. FGF21 treatment has been shown to inhibit hepatic growth hormone (GH) intracellular signaling. To evaluate GH axis involvement in FGF21 actions, transgenic mice overexpressing bovine GH were used. Expectedly, in response to FGF21 treatment control littermates showed metabolic improvements whereas GH transgenic mice resisted most of the beneficial effects of FGF21, except an attenuation of the innate hyperinsulinemia. Since FGF21 is believed to exert its effects mostly at the transcriptional level, we analyzed and observed significant upregulation in expression of various genes involved in carbohydrate and lipid metabolism, energy homeostasis, and antioxidant defense in FGF21-treated controls, but not in GH transgenics. The resistance of GH transgenic mice to FGF21-induced changes underlines the necessity of normal GH signaling for the beneficial effects of FGF21.


2018 ◽  
Author(s):  
Fahim Ebrahimi ◽  
Carole Wolffenbuttel ◽  
Claudine A Blum ◽  
Beat Muller ◽  
Philipp Schuetz ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document